Health Care • Biotechnology: Pharmaceutical Preparations
$19.90 ▼ -0.10
(-0.50%)
MKT CAP: $186.1M • VOL: 289.0K
52W L $16 52W H $47
YARW // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $570.0K | $501.0K | $424.0K |
| YoY Revenue Growth % | +13.8% | +18.2% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$29.7M | -$43.6M | -$29.3M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$26.5M | -$39.8M | -$28.5M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$33.1M | -$34.0M | -$25.3M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$33.1M | -$34.0M | -$25.3M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $24.0M | $19.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $27.8M | $52.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR YARW.